Sheffield, UK, 14/08/2023 – Phasefocus, a pioneer in cutting-edge life science solutions, is pleased to announce its latest product, the Livecyte T-Cell Killing Assay, is launching on the 12th September 2023. This revolutionary new assay addresses key challenges faced by researchers in investigating the efficacy and cytotoxicity of engineered T-cells in killing target cancers.

By offering unparalleled insights at the single-cell level, Livecyte empowers researchers to unlock new frontiers in cancer therapy development and evaluation. Current live cell imaging assays lack the ability to provide comprehensive and accurate insights into the dynamics and history of effector-target cell interactions. Existing solutions focus on population-level analysis and target cell death without exploring the effector interactions leading to death, leaving researchers with limited direct understanding of T-cell efficacy. Consequently, the gap between in-vitro and in-vivo T-cell therapy performance remains a significant challenge. The lack of precise single-cell data prevents researchers from fully understanding the intricacies of T-cell-target cell interactions, hindering the development of robust and reliable T-cell therapies. The failure of many T-cell therapies in in-vivo models and clinical studies underscores the pressing need for an in-vitro model that accurately recapitulates in vivo T-cell behaviour.

Livecyte revolutionizes T-cell killing assays by introducing advanced segmentation and tracking algorithms, enabling the automatic segmentation of target cells and label-free effector T-cells. Through this cutting-edge technology, Livecyte accurately tracks target cells over time, creating unique interaction profiles from the beginning of the experiment until target cell death.

Livecyte’s T-Cell Dashboard view compiles comprehensive metrics based on these interaction profiles, providing an array of information that summarises T-cell cytotoxicity and target cell recognition. Researchers gain a deeper understanding of T-cell-target cell avidity independently from attack potency, yielding greater depth of insight into how T-cells find and kill their targets.

Key Advantages of Livecyte T-Cell Killing Assay:

• An Invaluable Depth of Insight:  Livecyte employs advanced algorithms to automatically segment and track target cells, eliminating the need for manual, error-prone analysis.
• The Livecyte T-Cell Dashboard presents comprehensive metrics based on interaction profiles, offering a wealth of data on T-cell cytotoxicity and target cell recognition.
• Livecyte’s ability to independently quantify target cell death and T-cell interaction history at the single cell level, provides a profound understanding of T-cell behaviour leading to killing.
• All this is achieved without the need to fluorescently label T-cells which could alter their natural behaviour.

With the Livecyte T-Cell Killing Assay, researchers can now tackle the challenges of Tcell or natural killer cell therapy head-on, unlocking new potentials for cancer treatment and ultimately leading to more effective therapies for patients worldwide. Phasefocus CEO Martin Humphry said, “We are proud to be able to present this new offering to the market. CAR T-cell immunotherapy is a large and rapidly growing field and being able to bring the unique information-rich data that only Livecyte produces is both scientifically and commercially exciting.”

About Phasefocus:

Phasefocus is changing what is possible in live cell assays, helping scientists uncover subtle differences in cell behaviour across whole cell populations. The company’s products are based on a patented and award-winning computational imaging technology, called ptychography.

From automated characterisation of live cell behaviour, to world-record-setting electron microscopy, Phasefocus is enabling advances in many diverse areas of scientific research.

Livecyte, Phasefocus’s flagship product, delivers an unprecedented level of singlecell data from live cells. High-contrast label-free imaging, correlative fluorescence and powerful automated image analysis algorithms result in high-content time-lapse outputs from standard 96-well plate assays.

For enquiries, please contact:

Peter Djali PhD

Head of European Business Development

Email: [email protected]

Phone: +44(0) 7706 802291

Follow Phasefocus on LinkedIn and Twitter for the latest updates.